Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34055827

about

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer DNA damage response and prostate cancer: defects, regulation and therapeutic implications TopBP1 Governs Hematopoietic Stem/Progenitor Cells Survival in Zebrafish Definitive Hematopoiesis Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Molecular pathways and targets in prostate cancer c-Myb Binding Sites in Haematopoietic Chromatin Landscapes Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.New advances in genitourinary cancer: evidence gathered in 2014.Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.MYB is a novel regulator of pancreatic tumour growth and metastasis.New targets for resistant prostate cancer.Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.ATR/CHK1 inhibitors and cancer therapy.Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.Transcriptional profile of ethylene glycol monomethyl ether-induced testicular toxicity in rats.Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer.Molecular and cellular mechanisms of castration resistant prostate cancer.Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance.Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.

P2860

Q26745686-D6188821-C68E-4A08-A20E-24F9DE1867ED Q26751237-16E541C8-5CD6-4D48-B75D-59884062F5D1 Q26829155-1F5E2162-39D0-43C6-805E-B334257AEAFF Q27310778-A088A19B-8E08-4340-8B01-A009D34FBBA5 Q33798999-E25B53C3-F398-4949-8801-AA61F0C8FA57 Q34365632-29003BCF-1440-4ED2-A099-F46B6D0996D3 Q35711929-B3D5CFC9-CE68-4914-ABFB-4694B38AEE70 Q37022406-7E9C2152-AF18-46CF-82B8-4DC038FD267A Q37564733-469764BF-D07B-4B77-901C-744B8AC73BC4 Q37698312-8C917CE5-0B76-4818-BD4D-AB3F7A604811 Q38259197-B882BD22-9632-4CBC-B013-B868DCA5F575 Q38557894-532A138C-D196-47A7-A866-9C59E721EB82 Q38723072-89DC1621-FB87-41A7-9AB3-E873BD2F77CC Q38757645-2758ACB2-DFA4-44C7-9623-5CE72E0BB0F2 Q40258666-F33F2973-1096-43CE-B155-712696F6E438 Q41842858-E7AAC657-39A7-4C6E-B2FF-16CEB231CC23 Q42981809-DDBEADF8-A216-4411-BF36-C20771FECEFD Q47119992-BF774E2D-1B31-4F29-87BB-A8A4EC494F24 Q47164964-34C6DF3E-0309-4A99-8B8E-C40000DEC390 Q47595568-FA6C658F-A0CD-4B82-BAA1-ABFD14BD8D50 Q47622968-D358EDD4-E282-4099-981F-1596EEC61E6B Q48110323-10DB8527-9627-4C28-9F27-61B5DC9D5C37 Q51002092-AF4F2EAF-F40C-42FA-BD43-E2FE685F51AA Q52541424-06E0D7A3-037E-44A6-A92D-FA9A762580D8 Q52608488-BBC61647-04CF-4419-8FF9-87FDF24A8667 Q54949068-0234E4A8-0C37-4A76-979C-F466DF57286F Q55331819-7AA47924-6444-43C9-B908-5E2C1AE149AA

P2860

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34055827

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeting poly(ADP-ribose) pol ...... ion-resistant prostate cancer.

@ast

Targeting poly(ADP-ribose) pol ...... ion-resistant prostate cancer.

@en

type

label

Targeting poly(ADP-ribose) pol ...... ion-resistant prostate cancer.

@ast

Targeting poly(ADP-ribose) pol ...... ion-resistant prostate cancer.

@en

prefLabel

Targeting poly(ADP-ribose) pol ...... ion-resistant prostate cancer.

@ast

Targeting poly(ADP-ribose) pol ...... ion-resistant prostate cancer.

@en

P1433

Q34055827-B2A1BC5A-3D09-4C0B-912D-7A467B8AEA12

P1476

Q34055827-1323E90E-F8D8-4E0C-AF86-8E32D5594D8E

P2093

Q34055827-071796AA-C349-4385-9472-D33ABC20DF0D

Q34055827-225E7FCF-9EC3-4669-B4CA-A656B239DC78

Q34055827-2A8A1D0B-DA82-4834-A790-007CE7970BD0

Q34055827-3AB3C5B4-AF2D-4A61-B17C-F0EC814CCCA0

Q34055827-3F15E43A-98B3-4670-92A6-1EDAA2314F45

Q34055827-42FDC113-A506-46CA-A46E-FCFE17EB49B8

Q34055827-5E14ED1F-09B9-4673-B9E7-29B36BB4BC3E

Q34055827-61C57DD9-244C-4968-95EB-59EB8EE31058

Q34055827-7412EB75-436D-47B3-9C2F-B3905D0E6210

Q34055827-7646CF3E-3055-426D-B039-9E4F39193190

P2860

Q34055827-077CF0A2-E09F-4B4D-A5EE-9E849DD0A3B3

Q34055827-09C9C746-3050-46E4-AD17-CF9BA78201BC

Q34055827-23B29DE6-C666-4795-9CFD-EC5B3F39226A

Q34055827-24C93C51-17F3-4D7C-A74D-C77729C60B76

Q34055827-37D2F925-742C-4718-8E45-020A671BD573

Q34055827-395B006D-A401-474A-8C38-4E297E9139B8

Q34055827-3C9DA1DE-C07D-488C-A488-691E782AB385

Q34055827-47390AFA-1E11-4C48-B386-233C7BE76C93

Q34055827-4C3C0518-03B6-4F42-AA27-4D0023862012

Q34055827-54A9DFA3-6FA4-4B71-B9AE-9292992CEC84

P304

Q34055827-3A4501BF-20BB-4705-A5D3-A58D38906F89

P31

Q34055827-F9E31FE3-6227-4D38-92C6-A10001C0FED2

P356

Q34055827-44F68B53-5139-4C3C-A05B-184CF845AD87

P433

Q34055827-909D297A-3E41-415D-9292-AD7ECA6B7A5C

P478

Q34055827-BC8B96F8-8B1E-432D-A5B2-D76A3DB3E982

P50

Q34055827-779883CE-49A4-49B2-B8C8-87216243BB44

P577

Q34055827-8ED0DB44-A5C4-4B27-9602-80E18C5E78B2

P698

Q34055827-B82639FE-ED6F-4FE8-9501-BCA2981A1D56

P921

Q34055827-F3AAE42C-B1E4-4F7A-B0DC-05C3690892DA

P932

Q34055827-38738236-A931-4E5F-B91A-0A4BADC2BC5C

P356

SCISIGNAL.2005070

P1433

Science Signaling

P1476

Targeting poly(ADP-ribose) pol ...... ion-resistant prostate cancer.

@en

P2093

Ana M Aparicio

http://www.w3.org/2001/XMLSchema#string

Bradley Broom

http://www.w3.org/2001/XMLSchema#string

Chengzhen Ren

http://www.w3.org/2001/XMLSchema#string

Eleni Efstathiou

http://www.w3.org/2001/XMLSchema#string

Elsa M Li Ning Tapia

http://www.w3.org/2001/XMLSchema#string

Guang Yang

http://www.w3.org/2001/XMLSchema#string

Hirayama Takahiro

http://www.w3.org/2001/XMLSchema#string

Jianhua Yin

http://www.w3.org/2001/XMLSchema#string

Jianxiang Wang

http://www.w3.org/2001/XMLSchema#string

Ju-Seog Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer

Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma

The DNA Damage Response: Making It Safe to Play with Knives

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

ATR: an essential regulator of genome integrity

Androgen receptor in prostate cancer

Principles of cancer therapy: oncogene and non-oncogene addiction

PARP inhibition: PARP1 and beyond

P304

ra47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCISIGNAL.2005070

http://www.w3.org/2001/XMLSchema#string

P433

326

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24847116

http://www.w3.org/2001/XMLSchema#string

P921

P932

4135429

http://www.w3.org/2001/XMLSchema#string